<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01345526</url>
  </required_header>
  <id_info>
    <org_study_id>E-VITA</org_study_id>
    <nct_id>NCT01345526</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream</brief_title>
  <official_title>A Double Blind Placebo Controlled Randomized Phase II Study Evaluating the Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream in First Line mCRC Patients Treated With Erbitux and FOLFIRI.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this Phase 2, two-arm, randomized, double blind placebo controlled study is to
      evaluate the efficacy of combination therapy of doxycycline and Vitamin K1 compared to
      doxycycline plus placebo for the prevention of acne-like skin rash in mCRC patients receiving
      first line cetuximab treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of acne-like skin rash grade ≥ 2 (according to the CTCAE version 4.02) during the 8 weeks of skin treatment.</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Metastatic colorectal cancer, Doxycycline, Vitamin K1 Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic colorectal cancer, Doxycycline, Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reconval K1 Cream</intervention_name>
    <arm_group_label>Metastatic colorectal cancer, Doxycycline, Vitamin K1 Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reconval Cream</intervention_name>
    <arm_group_label>Metastatic colorectal cancer, Doxycycline, Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be given

          -  Patient ≥ 18 years

          -  Histologically proven and measurable metastatic adenocarcinoma of the colon or rectum
             (according to modified RECIST criteria v.1.1)

          -  Patients eligible for Erbitux and FOLFIRI treatment K-Ras wild type tumour

          -  Metastatic disease

          -  Life expectancy of at least 12 weeks

          -  WHO performance status of 0 or 1

          -  Effective contraception for both male and female patients if the risk of conception
             exists

          -  Adequate organ function

          -  Adequate bone marrow, hepatic and renal function (Hemoglobin &gt; 10.0 g/dL, platelet
             count &gt; 100 x 109/L, absolute neutrophil count &gt; 1.5 x 109/L; ALAT, ASAT &lt; 2.5 x ULN
             (upper limit of normal range) or &lt; 5x ULN in case of liver metastasis; Alkaline
             phosphatase &lt; 2.5 x ULN; Total bilirubin &lt; 1.5 x ULN; Creatinine clearance &gt; 50 mL/min
             (calculated according to Cockcroft and Gault formula)).

        Exclusion Criteria:

          -  Prior treatment for metastatic disease (adjuvant therapy with 5-FU/oxaliplatin based
             regimens) allowed if stopped 6 months prior to registration on study

          -  Prior treatment with EGFR inhibitor

          -  Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to study
             entry

          -  Administration of any investigational drug or agent/procedure, i.e. participation in
             another trial within 4 weeks before beginning treatment with study drugs

          -  Concurrent chronic systemic immune therapy, chemotherapy, radiation therapy or hormone
             therapy not indicated in the study protocol

          -  Any active dermatological condition &gt; grade 1 at baseline possibly interfering with or
             influencing the results or conduct of the present study

          -  Brain metastasis (known or suspected)

          -  Significant impairment of intestinal resorption (e.g. chronic diarrhea, inflammatory
             bowel disease)

          -  Any other uncontrolled concomitant illness, including serious uncontrolled
             intercurrent infection

          -  Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or
             IV, unstable angina pectoris, history of myocardial infarction within the last twelve
             months, significant arrhythmias)

          -  Known allergy or any other adverse reaction to any of the study drugs or to any
             related compound.

          -  Any organ allograft requiring immunosuppressive therapy.

          -  Pregnancy (absence to be confirmed by serum/urine beta human chorion gonadotrophin
             (HCG)) or breast-feeding.

          -  Other previous malignancy within 5 years, with exception of a history of a previous
             basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix surgically
             cured or adequately treated.

          -  Known drug abuse / alcohol abuse

          -  Legal incapacity or limited legal capacity

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and followup schedule; those conditions
             should be discussed with the patient before registration in the trial.

          -  Medical or psychological condition which, in the opinion of the investigator, would
             not permit the patient to complete the study or meaningfully sign informed consent.

          -  Known M. Meulengracht (Gilbert´s disease) or DPD-insufficiency

          -  Known coagulation disorders

          -  Ongoing or planned treatment with coumarin derivates
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Hofheinz, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsmedizin Mannheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralf Hofheinz, Prof.</last_name>
    <phone>+49 621 383 2855</phone>
    <email>Ralf.Hofheinz@umm.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Unversity Hospital Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Hofheinz, Prof.</last_name>
      <phone>+49 621 383 2855</phone>
      <email>Ralf.Hofheinz@umm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janja Ocvirk, Prof.</last_name>
      <phone>+ 386 15879220</phone>
      <email>jocvirk@0nko-i.si</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2011</study_first_posted>
  <last_update_submitted>April 28, 2011</last_update_submitted>
  <last_update_submitted_qc>April 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ralf Hofheinz</name_title>
    <organization>University Hospital Mannheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

